REGENXBIO (NASDAQ:RGNX – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Insider & Institutional Ownership
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
REGENXBIO has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Genelux has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Profitability
This table compares REGENXBIO and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| REGENXBIO | -112.58% | -220.07% | -46.04% |
| Genelux | N/A | -205.85% | -138.79% |
Valuation & Earnings
This table compares REGENXBIO and Genelux”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| REGENXBIO | $170.44 million | 2.61 | -$193.88 million | ($3.79) | -1.78 |
| Genelux | $10,000.00 | 8,776.56 | -$32.15 million | ($0.86) | -2.26 |
Genelux has lower revenue, but higher earnings than REGENXBIO. Genelux is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for REGENXBIO and Genelux, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| REGENXBIO | 1 | 3 | 9 | 1 | 2.71 |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
REGENXBIO currently has a consensus target price of $23.17, indicating a potential upside of 243.46%. Genelux has a consensus target price of $20.00, indicating a potential upside of 930.93%. Given Genelux’s stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than REGENXBIO.
About REGENXBIO
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
